<div id="readability-page-1"><p><span>Plus Therapeutics (NASDAQ:PSTV - Get Free Report)</span>'s stock had its &#34;buy&#34; rating restated by research analysts at D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They currently have a $5.00 target price on the stock.</p><p>Several other equities research analysts also recently issued reports on the company. Ascendiant Capital Markets cut their price target on Plus Therapeutics from $21.00 to $19.00 and set a &#34;buy&#34; rating for the company in a report on Friday, November 21st. D Boral Capital upgraded shares of Plus Therapeutics from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Wednesday, September 3rd. Maxim Group decreased their price target on shares of Plus Therapeutics from $4.00 to $3.00 and set a &#34;buy&#34; rating on the stock in a research note on Monday, August 18th. HC Wainwright  reissued a &#34;buy&#34; rating and issued a $2.00 price target on shares of Plus Therapeutics in a report on Wednesday, November 26th. Finally, Wall Street Zen upgraded Plus Therapeutics from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, August 16th. One analyst  has rated the stock with a Strong Buy rating, four have given a Buy rating, one  has assigned  a Hold rating and one  has given a Sell rating to the company. Based on data from MarketBeat.com, the stock  has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $7.25.</p><div><p><span></span><span>Get <strong>Plus Therapeutics</strong> alerts:</span></p></div><p><b>Check Out Our Latest Research Report on Plus Therapeutics</b></p><h2>Plus Therapeutics Stock Down 7.4%</h2><p>Shares of NASDAQ:PSTV traded down $0.05 during midday trading on Monday, reaching $0.57. 4,149,573 shares of the company were exchanged, compared to its average volume of 18,938,781. The firm has a market cap of $77.65 million, a PE ratio of -0.25 and a beta of 0.77. The stock has a fifty day simple moving average of $0.60 and a two-hundred day simple moving average of $0.48. Plus Therapeutics has a fifty-two week low of $0.16 and a fifty-two week high of $2.31. </p><p>Plus Therapeutics (NASDAQ:PSTV - Get Free Report) last announced its quarterly earnings results on Thursday, October 30th. The company reported ($0.04) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.02). The business had revenue of $1.40 million for the quarter, compared to analysts' expectations of $1.50 million.  As a group, analysts forecast that  Plus Therapeutics will post -2.3 earnings per share for the current year. </p><h2>Institutional Trading of Plus Therapeutics</h2><p>Large investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in shares of  Plus Therapeutics during the 1st quarter valued at approximately $38,000.  Jane Street Group LLC acquired a new stake in  Plus Therapeutics in the second quarter valued at approximately $41,000.  Susquehanna International Group LLP bought a new stake in shares of  Plus Therapeutics during the third quarter worth $46,000.  Scientech Research LLC bought a new stake in shares of  Plus Therapeutics during the third quarter worth $100,000.  Finally, Altium Capital Management LLC acquired a new position in shares of  Plus Therapeutics during the third quarter worth $628,000. Institutional investors and hedge funds own  3.28% of the company's stock. </p><h2>Plus Therapeutics Company Profile</h2> (Get Free Report)<p>Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.</p><h2>Read More</h2><ul><li>Five stocks we like better than Plus Therapeutics</li><li>Growth Investing: Should You Adopt This Investing Strategy in 2022?</li><li>NVIDIA’s 13F Reveals 2 Q3 Winners—And 1 Painful Miss</li><li>Low PE Growth Stocks: Unlocking Investment Opportunities</li><li>Why Silver Beat Gold and the S&amp;P in 2025—And What Comes Next</li><li>Stock Sentiment Analysis: How it Works</li><li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFNUVg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFNUVg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Plus Therapeutics Right Now?</h2><p>Before you consider Plus Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Plus Therapeutics wasn't on the list.</p><p>While Plus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PSTV

<p>D. Boral Capital reaffirmed a "buy" rating for Plus Therapeutics with a $5.00 price target. Other analysts have varied ratings, with a consensus of "Moderate Buy" and a target price of $7.25. The stock recently traded at $0.57, down 7.4%. Plus Therapeutics focuses on cancer treatments, with institutional investors holding 3.28% of shares. Recent earnings missed expectations, with a reported EPS of ($0.04) and revenue of $1.40 million.</p>

Plus Therapeutics' (PSTV) Buy Rating Reiterated at D. Boral Capital